Patents Examined by Abdel A. Mohamed
  • Patent number: 7683034
    Abstract: The invention relates to a process for the-inhibition of the DNA synthesis necessary for the proliferation of human sebaceous cells (sebocytes) by the isolated or joint effect of inhibitors of alanyl aminopeptidase (APN) and dipetidyl peptidase IV (DP IV) expressed by these cells. The DNA synthesis (proliferation) of human sebaceous cells is inhibited by the administration of the inhibitors of APN and/or of DP IV depending on the dose. Our invention shows that, for a therapy and for a prevention of dermatological diseases with sebaceous hyperproliferation and modified conditions of differentiation, the application of inhibitors of the above-mentioned enzymes and of corresponding pharmaceutical preparations and dosage forms thereof is suitable.
    Type: Grant
    Filed: March 7, 2003
    Date of Patent: March 23, 2010
    Assignee: IMTM GmbH
    Inventors: Siegfried Ansorge, Harald Gollnick, Klaus Neubert, Christos Zouboulis, Jurgen Faust, Uwe Lendeckel, Dirk Reinhold, Robert Vetter
  • Patent number: 7674451
    Abstract: The present invention relates to the use of at least one peptide, with the sequence (AA)n -Arg-Gly-Ser-(AA)n, where (AA) is any amino acid or one of its derivatives, and N is an integer between 0 and 3, as an active ingredient, in or for the preparation of a cosmetic and/or dermatological and/or pharmaceutical composition. The invention also relates to its use in order to treat, inter alia, the cutaneous manifestations of aging and/or its use in order to act against cellulite. The invention is, in the same way, related to a composition containing it as well as a process of cosmetic treatment of the skin using the said peptide or the said composition.
    Type: Grant
    Filed: February 14, 2008
    Date of Patent: March 9, 2010
    Assignee: ISP Investments Inc.
    Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
  • Patent number: 7671028
    Abstract: The present application discloses W-rich peptide that is useful for inhibiting FPR class receptor activity.
    Type: Grant
    Filed: February 3, 2005
    Date of Patent: March 2, 2010
    Assignees: POSTECH Foundation, POSCO, POSTECH Academy-Industry Foundation
    Inventors: Pann-Ghill Suh, Yoe-Sik Bae, Sung Ho Ryu, Tae Hoon Lee, Ha Young Lee, Eun Jin Jo, Jung-Im Kim, Hyun-Kyu Kang, Richard D. Ye, Jong-Young Kwak
  • Patent number: 7671027
    Abstract: The present invention concerns the use of an agonist of an hypothalamic hormone for the preparation of a pharmaceutical agent to support the luteal phase during infertility treatment of female mammals and more specifically of woman. According to this invention, the pharmaceutical agent is suitable to be used for supporting the luteal phase after a spontaneous ovulation or after stimulation of follicular growth, trigger of final follicular maturation and ovulation with one or several additional agents.
    Type: Grant
    Filed: December 29, 2003
    Date of Patent: March 2, 2010
    Assignee: PregLem S.A.
    Inventor: Ernest Loumaye
  • Patent number: 7662777
    Abstract: A method for the treatment and/or prevention of mucositis due to an antitumour treatment which comprises the administration of a composition containing suiglicotide to a patient in needs of said antitumour treatment.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: February 16, 2010
    Assignee: Gentium SpA
    Inventors: Massimo Iacobelli, Laura Iris Ferro
  • Patent number: 7651997
    Abstract: The present invention relates to tamandarin and didemnin analogs which have a deoxo-proline residue or a dehydro-proline residue in their structure. These analogs are useful as anti-cancer agents and for other purposes. Methods of making these analogs and methods of using them as inhibitors of protein synthesis, cell growth, and tumorigenesis and as enhancers of apoptosis are also provided.
    Type: Grant
    Filed: June 20, 2006
    Date of Patent: January 26, 2010
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Madeleine M. Joullie, Bo Liang, Xiaobin Ding
  • Patent number: 7648700
    Abstract: A method of inducing bone formation in a subject in need of such inducement comprises the steps of mechanically inducing an increase in osteoblast activity in the subject and elevating blood concentration of at least one bone anabolic agent in the subject. The method steps may be performed in any order, but in sufficient time proximity that the elevated concentration of the anabolic agent and the mechanically induced increase in osteoblast activity overlaps. The method may additionally comprise providing the subject with an elevated blood concentration of at least one antiresorptive agent, wherein the elevated concentration is sufficient to prevent resorption of new bone growth produced due to the osteoblast activity. Use of the method permits targeting of specific bones of the subject for bone production and preservation, faster bone production and earlier discontinuation of bone anabolic pharmaceuticals. Kits adapted for performing the method are provided.
    Type: Grant
    Filed: August 16, 2007
    Date of Patent: January 19, 2010
    Assignees: Unigene Laboratories, Inc., Yale University
    Inventors: Agnes Vignery, Nozer M. Mehta, James P. Gilligan
  • Patent number: 7648965
    Abstract: A method of inducing bone formation in a subject in need of such inducement comprises the steps of mechanically inducing an increase in osteoblast activity in the subject and elevating blood concentration of at least one bone anabolic agent in the subject. The method steps may be performed in any order, but in sufficient time proximity that the elevated concentration of the anabolic agent and the mechanically induced increase in osteoblast activity overlaps. The method may additionally comprise providing the subject with an elevated blood concentration of at least one antiresorptive agent, wherein the elevated concentration is sufficient to prevent resorption of new bone growth produced due to the osteoblast activity. Use of the method permits targeting of specific bones of the subject for bone production and preservation, faster bone production and earlier discontinuation of bone anabolic pharmaceuticals. Kits adapted for performing the method are provided.
    Type: Grant
    Filed: November 7, 2005
    Date of Patent: January 19, 2010
    Assignees: Unigene Laboratories Inc., Yale University
    Inventors: Agnès Vignery, Nozer M. Mehta, James P. Gilligan
  • Patent number: 7612163
    Abstract: A PK2? peptide is described, which, as an agonist of prokineticin receptor 1, is useful for treating lung and gastrointestinal diseases or disorders mediated by PKR1 activity.
    Type: Grant
    Filed: March 29, 2005
    Date of Patent: November 3, 2009
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Changlu Liu, Jingcai Chen
  • Patent number: 7605232
    Abstract: A method of concentrating proteins from whole blood comprising exposing whole blood to covalently crosslinked hydrogel to remove water from the blood into the hydrogel to thereby concentrate the proteins in the whole blood. The hydrogel may absorb, for example, 50% or 90% of the water from the blood while excluding proteins with a weight of more than about 15,000 Daltons. In some embodiment, the hydrogels are dry, sterile, and spherical.
    Type: Grant
    Filed: March 20, 2007
    Date of Patent: October 20, 2009
    Assignee: Incept LLC
    Inventor: Chandrashekhar P. Pathak
  • Patent number: 7601515
    Abstract: A process is provided for the preparation of albumin from a yeast culture medium which has extremely low levels of or is essentially free of colorants, metal ions, human proteins, host proteins, fragments of albumin, polymers or aggregates of albumin and viruses, and which is essentially non-glycated, relatively high in free thiol and with an intact C-terminus. The process comprises separating the yeast from the culture medium to yield an albumin solution; subjecting the albumin solution to positive mode cation exchange, affinity, and positive mode anion exchange chromatography; and concentrating and formulating the albumin with sodium octanoate and sodium chloride.
    Type: Grant
    Filed: April 23, 2007
    Date of Patent: October 13, 2009
    Assignee: Novozymes Biopharma UK Limited
    Inventors: Andrew Robert Goodey, Darell Sleep, Hendrik Van Urk, Stephen Berezenko, John Rodney Woodrow, Richard Alan Johnson, Patricia Carol Wood, Stephen James Burton, Alan Victor Quirk
  • Patent number: 7597882
    Abstract: Some aspects of this disclosure relate to a method for crosslinking a biological fluid comprising combining a biological fluid with a crosslinker to covalently crosslink proteins endogenous to the biological fluid to form a crosslinked gel. Examples of a biological fluid are blood, plasma, or serum.
    Type: Grant
    Filed: April 24, 2007
    Date of Patent: October 6, 2009
    Assignee: Incept LLC
    Inventors: Chandrashekhar P. Pathak, Amarpreet S. Sawhney, James H. Dreher
  • Patent number: 7595294
    Abstract: Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented. Methods of using the vasoactive intestinal polypeptide compositions are also disclosed.
    Type: Grant
    Filed: April 10, 2006
    Date of Patent: September 29, 2009
    Assignee: Transition Therapeutics, Inc.
    Inventor: John Nestor
  • Patent number: 7592418
    Abstract: Biocompatible crosslinked polymers, and methods for their preparation and use, are disclosed in which the biocompatible crosslinked polymers are formed from water soluble precursors having electrophilic and nucleophilic functional groups capable of reacting and crosslinking in situ. Methods for making the resulting biocompatible crosslinked polymers biodegradable or not are provided, as are methods for controlling the rate of degradation. The crosslinking reactions may be carried out in situ on organs or tissues or outside the body. Applications for such biocompatible crosslinked polymers and their precursors include controlled delivery of drugs, prevention of post-operative adhesions, coating of medical devices such as vascular grafts, wound dressings and surgical sealants. Visualization agents may be included with the crosslinked polymers.
    Type: Grant
    Filed: February 13, 2008
    Date of Patent: September 22, 2009
    Assignee: Incept LLC
    Inventors: Chandrashekhar P. Pathak, Amarpreet S. Sawhney, Peter G. Edelman
  • Patent number: 7566691
    Abstract: Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented. Methods of using the vasoactive intestinal polypeptide compositions are also disclosed.
    Type: Grant
    Filed: October 7, 2005
    Date of Patent: July 28, 2009
    Assignee: Transition Therapeutics, Inc.
    Inventor: John Nestor
  • Patent number: 7544781
    Abstract: A process for producing a polypeptide, by reacting a peptide component (A) represented by formula (1) below with a peptide component (B) represented by formula (2) below and optionally a compound (C) represented by formula (3) below, to obtain said polypeptide: (1) X-(Pro-Y-Gly)n-OH, wherein: X represents H or the group HOOC—(CH2)m—CO— and m denotes an integer of 1 to 18, Y represents Pro or Hyp, and n denotes an integer of 1 to 20; (2) X-(Z)r—OH, wherein X represents H or the group HOOC—(CH2)m—CO— and m denotes an integer of 1 to 18, Z represents a peptide chain comprising 1 to 10 amino acid residue(s), and r denotes an integer of 1 to 20; and (3) H2N—R—NH2, wherein R represents a linear or branched alkylene group; and further wherein the ratio of the peptide component (A) relative to the peptide component (B) is 100/0 to 30/70 (mol %); provided that in the case where X represents the group HOOC—(CH2)m—CO— and m has the same meaning as defined above in formula (1) and/or (2), the amount of compou
    Type: Grant
    Filed: July 26, 2007
    Date of Patent: June 9, 2009
    Assignee: PHG Corporation
    Inventors: Masao Tanihara, Chikara Otsuki, Hiroshi Mikami, Hisao Kinoshita
  • Patent number: 7544368
    Abstract: Embodiments of the present invention are directed to three-dimensional porous structures for modulating intraocular pressure. The structures can include a mixture of copolymers, for example, collagen and glycosaminoglycan.
    Type: Grant
    Filed: May 31, 2007
    Date of Patent: June 9, 2009
    Assignee: Life Spring Biotech Co., Ltd.
    Inventors: Wei-Cherng Hsu, Jo-Yi Hsiao, Hsiao-Cheng Yen
  • Patent number: 7541330
    Abstract: A conjugate of an active agent and a targeting moiety having affinity for a target cell, in which the active agent has been modified by attachment of a cell membrane-impermeabilizing group so that, if the active agent so modified is cleaved from the conjugate in the blood plasma instead of inside the target cell, the cell membrane-impermeabilizing group prevents or limits entry of the modified active agent into cells, thus reducing its systemic or non-specific adverse effects, including toxicity.
    Type: Grant
    Filed: June 9, 2005
    Date of Patent: June 2, 2009
    Assignee: Kosan Biosciences Incorporated
    Inventors: Daniel V. Santi, Brian Hearn
  • Patent number: 7541329
    Abstract: Compositions and methods for reducing hypercholesterolemia and, accordingly, the risk of cardiovascular disease, are provided. Such compositions may comprise isolated oil body associated proteins. Additionally provided are foodstuffs to which one or more oil body associated proteins have been added. The compositions employed in the invention may further comprise additive compounds, for example, a saponin, an isoflavone, a phospholipid, a carbohydrate substantially resistant to digestion, or a combination thereof. The methods and compositions of the invention may be used to lower cholesterol and other lipid levels in subjects to achieve a reduction in the risk of cardiovascular disease.
    Type: Grant
    Filed: April 17, 2003
    Date of Patent: June 2, 2009
    Assignee: Monsanto Technology LLC
    Inventors: Neal A. Bringe, Kanthasamy Karunanandaa
  • Patent number: RE41287
    Abstract: The present invention relates to novel cyclic or constrained acyclic compounds which modulate the activity of G protein-coupled receptors and are useful in the treatment of conditions mediated by G protein-coupled receptors, for example, inflammatory conditions.
    Type: Grant
    Filed: June 25, 1998
    Date of Patent: April 27, 2010
    Assignee: Promics Pty Limited
    Inventors: David Fairlie, Stephen Maxwell Taylor, Angela Monique Finch, Allan Wong